


Backing Britain's AI Founders to start here, scale here, and win everywhere



Through our Strategic Assets Programme, we're providing £5 million to OpenImmune to build an open dataset that could help AI models better predict how patients' immune systems respond to biologic drugs. When the immune system reacts against a medicine, treatment can become less effective or cause harmful side effects. Better predictions could help researchers address these challenges earlier in drug development. The dataset, models and tools will be hosted in the UK and made openly available, giving researchers and drug developers across the world the opportunity to build on the work.

An amazing moment at Iso as we close our Series C funding round! We founded Iso on the conviction that AI can transform biology into a programmable science. We are clearly seeing this play out internally with our models’ capabilities translating into new potential medicines for patients. This funding will supercharge our efforts, so we can push even deeper into the hard problems of understanding disease biology, engineering the most exquisite molecules possible, and bringing new drugs to patients who need them. Lots more to come!
We’ve closed our $5 Billion funding round co-led by Greenoaks and Sequoia Capital to build the future of medicine and bioengineering with AI. isomorphiclabs.com/articles/…

Thrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease. We continue to make rapid progress reimagining drug design from first principles with AI to radically cut the time & cost to find new medicines. Gradually, then all at once...

We’re continuing to support Isomorphic Labs as part of their latest $5bn Series C funding round. Our conviction has always been that the UK can lead the world in applying AI to the hardest problems in science, and Isomorphic Labs embodies that ambition. We’re proud to continue our support and we look forward to continuing to work with Sir @demishassabis, @maxjaderberg and the entire Isomorphic Labs team as they work to realise that ambition and build the future of drug discovery.
We’ve closed our $5 Billion funding round co-led by Greenoaks and Sequoia Capital to build the future of medicine and bioengineering with AI. isomorphiclabs.com/articles/…

We’ve closed our $5 Billion funding round co-led by Greenoaks and Sequoia Capital to build the future of medicine and bioengineering with AI. isomorphiclabs.com/articles/…


We’re investing in @fractile_ai to build the next generation of frontier AI chips. Fractile is rethinking chip design from the ground up, bringing together hardware, software and machine learning. Its ambition is to make increasingly capable AI models faster and cheaper to run, with global ambitions in AI hardware.

We’re delighted to announce that Fractile has raised $720M in a Series C led by @thrivecapital @foundersfund @lightspeedvp and @redpoint, with further participation by brilliant new and existing investors.


We’re investing in @TendrilsCompute as they rethink general-purpose chip design, developing a new processor architecture to make parallel computing practical for a much wider range of applications.

Tendrils has raised $30M led by @benchmark to rebuild general-purpose computing. @jaltma is joining our board. At Tendrils, we believe that the future of general-purpose computing lies beyond legacy architectures for legacy software.

An ambitious state has backed British industrial science before. With @UKSovereignAI’s investment in @potentialsci_, we are backing British ingenuity, jobs and medical innovation again! 🇬🇧

A deep, technical chat between Hatem and @CorinWagen: simulated data at coupled-cluster accuracy, lead optimisation, the hardware lottery and building in the UK with @uksovereignai. Thanks @RowanSci for having us!
Yesterday, Potential Sciences came out of stealth to build a UK frontier lab for chemistry. I spoke with Hatem Helal, Potential's CEO, about what they're building and why their simulation-first approach complements other AI-for-science teams. rowansci.com/blog/a-conversa…
View quoted post ↗
AI for drug discovery has learned almost everything the existing experimental record can teach it. The next leap needs new data, and the laws of physics can supply it. Potential Sciences is out of stealth to solve this problem, backed by @uksovereignai and @Twinpathvc.